Opinion|Videos|May 16, 2025
Impact of CHE on Patient Quality of Life
Author(s)Raj Chovatiya, MD, PhD
An expert discusses how chronic hand eczema (CHE) significantly impacts patients' daily activities and work productivity, as painful symptoms and limitations make routine tasks challenging, while avoidance recommendations are often difficult to implement.
Advertisement
Video content above is prompted by the following:
Patient Impact of CHE
Key Themes:
- Functional limitations: Significant impairment in basic daily activities and professional responsibilities.
- Work productivity: Both presenteeism and absenteeism affect patients' occupational performance.
- Treatment challenges: Difficulty implementing avoidance strategies when exposures are occupationally necessary.
Notable Insights:
Dr Chovatiya described the cycle that patients experience: "Traditional medications, half-hearted avoidance behavior, or impossible-to-follow recommendations for avoidance behavior," highlighting the practical challenges patients face.
Advertisement
Related to this article
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Advertisement
Advertisement
Trending on HCPLive
1
New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity
2
Remibrutinib Receives FDA Approval for Symptomatic Dermographism
3
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5